Cenobamate, applied at concentrations in the clinically relevant range, resulted in the significant inhibition of Nav1.5 and Cav1.2 channels, which may explain the dose-dependent QTc shortening effects and the interdiction for administering the drug to patients with short QT syndrome. This evidence concerns the gene CACNA1C and short QT syndrome.